Article Details
Retrieved on: 2024-05-14 20:07:34
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Dyadic International Inc.'s progress in biotechnology, focusing on its successful clinical trials and vaccine development for COVID-19 and influenza, using its proprietary C1-cell protein production platform. These innovations address both human and animal health sectors.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here